8-K: Anteris DurAVR THV Shows Strong 30-Day Outcomes in Small Annuli

Anteris Technologies announced positive 30-day clinical outcomes for its DurAVR Transcatheter Heart Valve in 100 severe aortic stenosis patients with small aortic annuli.

Summary

• Anteris Technologies Global Corp. released 30-day clinical outcomes for its DurAVR Transcatheter Heart Valve (THV) in 100 severe aortic stenosis patients with small aortic annuli (aortic annulus area ≤ 404 mm²).
• The DurAVR THV demonstrated a favorable hemodynamic profile with a large effective orifice area (EOA) of 2.2 ± 0.3 cm² and a single-digit mean pressure gradient (MPG) of 8.2 ± 3.1 mmHg.
• Clinical safety outcomes at 30 days were positive, with no valve-related mortality and no moderate or severe paravalvular leak (PVL).
• The device achieved 97% freedom from moderate or severe prosthesis-patient mismatch (PPM), with an occurrence rate of just 3.0%. This compares favorably to 11.2% to 35.3% for current commercial devices in a similar patient cohort (SMART Trial).
• A technical success rate of 100% was achieved in the last 50 consecutive patient implants.
• This pooled analysis of 100 patients is derived from the ongoing EMBARK study and early feasibility studies (EFS) conducted in the United States and Europe.
• These results represent approximately 20% of the planned DurAVR enrollment for the all-comers randomized cohort of the global PARADIGM Trial (NCT07194265).

Sentiment

Score: 9

Explanation: The clinical outcomes presented are exceptionally strong, particularly the low rate of prosthesis-patient mismatch (PPM) compared to existing commercial devices. This data suggests a significant competitive advantage for DurAVR THV in a challenging patient population, indicating high potential for future commercial success and positive impact on patient care.

Positives

• Favorable hemodynamic profile with a large effective orifice area (EOA) of 2.2 ± 0.3 cm² and a single-digit mean pressure gradient (MPG) of 8.2 ± 3.1 mmHg.
• No valve-related mortality at 30 days.
• No moderate or severe paravalvular leak (PVL) at 30 days.
• Achieved 97% freedom from moderate or severe prosthesis-patient mismatch (PPM), with an occurrence rate of only 3.0%. This is significantly lower than the 11.2% to 35.3% reported for current commercial devices in similar patient populations.
• Demonstrated a 100% technical success rate in the last 50 consecutive patient implants.
• The consistent clinical profile observed across earlier and longer-term patient outcomes reinforces confidence in DurAVR's potential.

Risks

• Forward-looking statements are subject to a number of risks, uncertainties, and assumptions.
• Specific risks are described under "Risk Factors" in the Annual Report on Form 10-K for the fiscal period ended December 31, 2024.

Future Outlook

The company anticipates advancing the DurAVR THV toward commercialization. The consistent clinical profile from this pooled analysis, combined with 1-year results presented at TCT, serves as a potential proxy for the recently initiated global PARADIGM Trial, a prospective, randomized controlled trial evaluating DurAVR THV's safety and effectiveness against commercially available TAVRs.

Management Comments

• "The DurAVR THV demonstrated high rates of technical and device success with encouraging 30-day hemodynamic outcomes, including very low PPM in small annuli patients. These results reflect a unique balance of balloon-expandable benefits characterised by high device success and low pacemaker rates, combined with a hemodynamic profile typically associated with self-expanding platforms." Prof. Dr. Ole De Backer, The Heart Centre, Rigshospitalet, Copenhagen University Hospital.
• "Achieving 97% freedom from moderate or severe PPM is clinically relevant, particularly in small annuli patients where the risk of PPM is amplified." Chris Meduri, M.D., Anteris Chief Medical Officer.
• "This consistency across earlier and longer-term patient outcomes reinforces our confidence in DurAVRs potential as we advance this life-saving technology toward anticipated commercialization." Wayne Paterson, Vice Chairman and CEO.

Industry Context

The transcatheter aortic valve replacement (TAVR) market is highly competitive, with a significant challenge being prosthesis-patient mismatch (PPM), especially in patients with small aortic annuli. PPM is a key predictor of valve failure and disease progression, and current commercial devices often struggle to achieve optimal outcomes in this patient subgroup. DurAVR THV's reported low PPM rate directly addresses a critical unmet need in this segment.

Comparison to Industry Standards

• DurAVR THV achieved 3.0% moderate or severe prosthesis-patient mismatch (PPM) in patients with small aortic annuli.
• This compares favorably to PPM rates ranging from 11.2% to 35.3% for current commercial devices, as reported in the SMART Trial (Herrmann HC et al., N Engl J Med. 2024).
• The results suggest DurAVR THV offers a superior hemodynamic profile, particularly in reducing PPM, compared to established TAVR technologies.

Stakeholder Impact

• Patients: Potential for significantly improved outcomes, particularly for those with small aortic annuli, due to reduced prosthesis-patient mismatch and favorable hemodynamics.
• Shareholders: Positive impact due to strong clinical data supporting the company's lead product, enhancing its market potential and competitive position.
• Medical Community: Provides compelling evidence for a novel TAVR device that addresses a critical challenge in aortic stenosis treatment.

Next Steps

• Continue the global PARADIGM Trial (NCT07194265), a prospective, randomized controlled trial evaluating DurAVR THV against commercially available TAVRs.
• Advance the DurAVR THV toward anticipated commercialization.

Key Dates

Recommendation

The clinical data for DurAVR THV is exceptionally strong, demonstrating superior outcomes, particularly in reducing prosthesis-patient mismatch (PPM) compared to current commercial devices. This addresses a significant unmet need in patients with small aortic annuli, a challenging subgroup. The 100% technical success rate in recent implants and the favorable hemodynamic profile further bolster confidence. These results position Anteris Technologies with a strong competitive advantage, indicating high potential for market penetration and future revenue growth upon commercialization. The initiation of the PARADIGM trial further de-risks the path to market.

Keywords

DurAVR THV, aortic stenosis, transcatheter heart valve, small aortic annuli, prosthesis-patient mismatch, PPM, ADAPT tissue, clinical outcomes, medical device, cardiology, TAVR, EMBARK study, PARADIGM trial